Immix Biopharma Inc.

Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical firm dedicated to advancing a category of specialized therapies known as Tissue-Specific Therapeutics (TSTx), with a focus on applications in oncology and inflammation. Currently, their primary candidate, IMX-110, is undergoing Phase Ib/IIa clinical trials in both the United States and Australia for the treatment of solid tumours.

Recent Financial and Business Updates:

• Second Quarter Income Statement Review:
  • Reported a net loss of around USD 3.6 million in the June 2023 quarter.
  • Loss from operations was reported to be USD3.72 million.
  • For the three-month period concluding on June 30, 2023, interest earnings amounted to USD128,848, while in the corresponding period of June 30, 2022, there were no interest earnings recorded.
• Balance Sheet Review:
  • Reported total assets of USD 15.5 million as of June 30, 2023.
  • Total liabilities amounted to USD 2.39 million as of June 30, 2023.
  • Total liabilities and stockholders’ equity as of June 30, 2023, was USD 15.56 million.
• Business Update:
  • Hsu Jason, who serves as a Director at Immix Biopharma, has purchased shares valued at USD 200,000 in the biotechnology firm.
  • This 10% owner obtained a total of 72,000 shares through several transactions, with prices ranging from USD 2.9299 to USD 2.42 per share.
  • As a result, Jason now possesses 757,000 shares through direct ownership and an additional 4 million shares through indirect ownership.

Technical Observation (on the daily chart)

The Relative Strength Index (RSI) over a 14-day period stands at 66.39, cooling from the overbought zone, with expectations of some consolidation before a continuation of the uptrend . Meanwhile, the stock price is above both the 21-day Simple Moving Average (SMA) and the 50-day SMA, therefore these SMA can act as short-term support in case the price corrects.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a “WATCH” rating is recommended for Immix Biopharma Inc. (NASDAQ: IMMX) at its closing price of USD3.05 as on September 20, 2023, at 7:15 am PDT.

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing. 

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

How to Read the Charts?

The yellow colour line reflects the 21-period simple moving average (SMA) while the blue line indicates the 50- period simple moving average (SMA). SMA helps to identify existing price trends. If the prices are trading above the 21-period and 50-period moving average, then it shows prices are currently trading in a bullish trend.

The orange colour line in the chart’s lower segment reflects the Relative Strength Index (14-Period) which indicates price momentum and signals momentum in trend. A reading of 70 or above suggests overbought status while a reading of 30 or below suggests an oversold status.

The red and green colour bars in the chart’s lower segment show the volume of the stock. The volume is the number of shares that changed hands during a given day. Stocks with high volumes are more liquid than stocks with lesser volume as liquidity in stocks helps with easier and faster execution of the order.

The Orange colour lines are the trend lines drawn by connecting two or more price points and used for trend identification purposes. The trend line also acts as a line of support and resistance.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock. 

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock. 

Stop-loss: It is a level to protect further losses in case of unfavourable movement in the stock prices. 

The reference date for all price data, currency, technical indicators, support, and resistance levels is September 20, 2023. The reference data in this report has been partly sourced from REFINITIV. 

Abbreviations

CMP: Current Market Price

SMA: Simple Moving Average

RSI: Relative Strength Index

USD: United States dollar 

Note: Trading decisions require a thorough analysis by individual. Technical reports in general chart out metrics that may be assessed by individuals before any stock evaluation. The above are illustrative analytical factors used for evaluating the stocks; other parameters can be looked at along with additional risks per se. Past performance is neither an indicator nor a guarantee of future performance.

Disclaimer

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.